Continuous cyclophosphamide, doxorubicin, vincristine, and prednisolone. A new, innovative protocol for diffuse aggressive lymphomas

Journal Article · Sun Apr 15 00:00:00 EDT 1990 · Cancer (Philadelphia); (USA)

DOI:https://doi.org/10.1002/1097-0142(19900415)65:8<1704::AID-CNCR2820650807>3.0.CO;2-R· OSTI ID:6946033

Banavali, S D; Advani, S H; Gopal, R; Agarwala, S; Dinshaw, K A; Saikia, T K; Pai, S K; Kurkure, P; Nair, C N; Gonsalves, M ^[1]

---

1. Tata Memorial Hospital, Bombay (India)

One hundred eight patients with aggressive non-Hodgkin's lymphoma (high and intermediate grade) were treated with a new protocol: continuous cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP). They were evaluated for long-term survival and pretreatment characteristics predictive of response and survival. Continuous CHOP protocol consists of initial 8 weeks of intensive chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone, followed by local/cranial radiotherapy and maintenance therapy. Complete remission (CR) was achieved in 84 of 108 (78%) patients; seven (6%) had a moderate response and 17 (16%) had a poor response. A statistically significant difference in CR rate was found only in patients with different stages. Seventeen of 84 (20%) complete responders have had a relapse of the disease. The median survival has not been reached. Results show an actuarial disease-free survival (DFS) of 77% for the 84 patients who had a complete response. The overall survival for all patients was 53% at 5 years of follow-up. The difference in DFS at the end of 5 years between different stages, main histologic subgroups, and age groups was not statistically significant. The toxicity observed was acceptable. Thus continuous CHOP appears to be an effective protocol for the treatment of intermediate-grade and high-grade lymphomas.

• OSTI ID: 6946033
• Journal Information: Cancer (Philadelphia); (USA), Vol. 65:8; ISSN 0008-543X
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
LYMPHOMAS
COMBINED THERAPY
ANTINEOPLASTIC DRUGS
DOXORUBICIN
PATIENTS
PREDNISOLONE
SURVIVAL CURVES
ADRENAL HORMONES
ANTI-INFECTIVE AGENTS
ANTIBIOTICS
CORTICOSTEROIDS
DISEASES
DRUGS
GLUCOCORTICOIDS
HYDROXY COMPOUNDS
IMMUNE SYSTEM DISEASES
KETONES
NEOPLASMS
ORGANIC COMPOUNDS
PREGNANES
STEROIDS
THERAPY
550603* - Medicine- External Radiation in Therapy- (1980-)
550600 - Medicine